Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Semaglutide, a medication used for obesity and type 2 diabetes, works by mimicking natural appetite-control signals. A team from the University of Gothenburg discovered that certain nerve cells in ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Structure planned to initiate a Phase 2b obesity study in Q4 2024. ... Oral semaglutide. GLP-1R agonist (peptide) 15.1% weight loss at 68 weeks / 16.6% discontinuation due to AEs.

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...

The Brief. After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended.

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

Key Takeaways. Semaglutide 2.4 mg could prevent nearly 2 million major cardiac events and over 1 million deaths in eligible patients. Uptake of semaglutide remains low due to cost, supply issues ...